Arena Pharmaceuticals (ARNA) 6.84 $ARNA
Arena Pharmaceuticals' Q1 Loss Widens 34% Despite Belviq's Sales Surge
Sean Williams, The Motley Fool - Motley Fool - Mon May 12, 3:50PM CDT
Arena Pharmaceuticals , a biopharmaceutical company primarily focused on weight control management drug Belviq, this afternoon reported strong sales growth of its lead product in the first quarter , but also produced a much wider net loss than in...
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2014 Financial Results
PR Newswire - Mon May 12, 3:03PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2014.
Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ® (lorcaserin HCl) CIV by 50%
PR Newswire - Fri May 09, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai plans to add more than 200 new contract sales representatives to its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600, triple the size from the commercial launch of BELVIQ in June 2013. Eisai expects this expansion of the sales force will become effective on July 1, 2014, and enable them to reach approximately 90,000 physicians in the United States.
Healthcare Companies Report Studies, Financial Results, and Upcoming Conferences - Analyst Notes on Vertex, PerkinElmer, PAREXEL, ACADIA Pharmaceuticals and Arena Pharmaceuticals
PR Newswire - Thu May 08, 11:31AM CDT
Today, Analysts Review released its analysts' notes regarding Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2188-100free.
ARNA June 27th Options Begin Trading
DividendChannel.com - Thu May 08, 10:02AM CDT
Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the June 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new June 27th contracts and identified...
Psoriasis - Pipeline Review, H1 2014: 110 Companies Profiled
M2 - Thu May 08, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vjq8/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 4SC AG - Acceleron Pharma, Inc. - Addex Therapeutics - Advancell - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Alcon, Inc. - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - AngioLab, Inc. - Apexigen, Inc. - ApoPharma Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Aurinia Pharmaceuticals Inc. - Avexxin AS - Basilea Pharmaceutica AG - Bionomics Limited - Brickell Biotech, Inc. - Can-Fite BioPharma Ltd. - Catabasis Pharmaceuticals, Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Cellceutix Corporation - Celltrion, Inc. For more information visit http://www.researchandmarkets.com/research/p6vjq8/psoriasis
Acute Coronary Syndrome - Pipeline Review, H1 2014: 21 Companies and 29 Drugs Profiled
M2 - Wed May 07, 12:15PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2f56rx/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Bayer AG - CSL Limited - GlaxoSmithKline plc - LG Life Sciences, Ltd. - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - Ligand Pharmaceuticals, Inc. - MedImmune, LLC - Medicure Inc. - Pfizer Inc. - Regado Biosciences, Inc. - Stealth Peptides Inc. - The Medicines Company - Viron Therapeutics, Inc. - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles: - cangrelor - rivaroxaban - BAY-818781 - REG-1 - clopidogrel bisulfate - VT-111a - CSL-112 - gevokizumab - losmapimod - MTP-131 - ZK-001 - PR-15 - temanogrel hydrochloride - MDCO-216 - losmapimod - LC-231306 - ACP-501 - PF-06282999 - Artpep-2 - DMI-4983 - LA-8045 - COR-3 - COR-2 - AEM-28 - Type 5 Adenylyl Cyclase Inhibitors - tirofiban hydrochloride transdermal - Liver X Receptor Modulator For Acute Coronary Syndrome - Anti Platelet Program - SD-970 For more information visit http://www.researchandmarkets.com/research/2f...e_coronary
A View on Ariad Pharma's Bloated Valuation
at The Street - Wed May 07, 11:49AM CDT
Even at $86 million in 2014 Iclusig sales, Ariad trades at a lofty and unjustified 13 times enterprise value. For comparison's sake, Medivation's EV/sales multiple is 9 -- and that's only counting U.S. sales of its growing prostate cancer drug...
VIVUS Blows Out Estimates, But For All the Wrong Reasons
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 9:03AM CDT
After the closing bell on Monday, VIVUS shares entered unchartered territory following the release of its first-quarter earnings report -- and by unchartered I mean actually up . VIVUS hasn't had the best of luck come earnings time. In fact,...
Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market 2014
M2 - Tue May 06, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mk3bhv/a_strategic) has announced the addition of the "A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market" report to their offering. Prescription drug therapy for the treatment of obesity is experiencing a revival of interest with new government incentives and the recent approval of 2 new drugs, with 2 more pending imminent approval. This research service focuses on the competitive landscape of prescription drugs for the treatment of obesity. A global product and pipeline assessment is provided for marketed and investigational products. Segmentation by drug class is provided along with additional supporting information, such as clinical-trial timelines and results, historical and projected launch timelines, regulatory guidelines for clinical trial design and approval, and global epidemiology by region. Executive Summary: - The FDA recently approved 2 new prescription obesity treatments: Arena Pharmaceuticals' Belviq (partnered with Eisai) launched in June 2013, and Vivus' Qsymia, which became available September 2012. These FDA approvalsthe first for obesity in more than a decadeadd new therapeutic options to a market previously comprising a single approved drug: Roche's Xenical. - A third new drug, Orexigen's Contrave, is pending FDA approval upon successful demonstration of cardiac safety in an ongoing trial for cardiovascular outcomes and resubmission of the new drug application (NDA) in December 2013. A decision is expected from the FDA June 10, 2014, and in the second half of 2014 from the EMA. o All three of these new drugs were initially rejected by the FDA, which sought additional confirmation of an acceptable safety profile. - Approval of the obesity indication for Novo Nordisk's Victoza (liraglutide) could come as soon as mid-2014, closely coinciding with the potential approval of Contrave. - Market uptake of Qsymia and Belviq has been below expectations, largely due to insurance reimbursement hurdles and possibly because of physician and patient concerns about safety. Contrave, if approved, may have better uptake in light of its designation as an uncontrolled substance and stronger marketing capabilities of partner Takeda, particularly to the primary care and diabetes communities. - Global medical and regulatory communities recognize the urgent need for the pharmacotherapeutic treatment of obesity when lifestyle interventions fail to adequately address excess body fat. - While numerous sympathomimetic amine anorectics such as phentermine, benzphetamine, and diethylpropion are available by prescription, association with serious side effects limits their use, and prescribing is mainly limited to bariatric surgeons. - The global market potential for safe and effective obesity therapies is significant; howeverthe discovery and development of efficacious weight-loss drugs that are safe enough for - chronic use has proved challenging for even the most capable pharmaceutical and biotech companies. - Ongoing research efforts are beginning to shed new light on the pathology of obesity, as recent discoveries of differential gene expression and genetic variants found in the different fat depots advance our understanding of why abdominal fat is more strongly associated with morbidity and mortality compared with subcutaneous adipose tissue. Discoveries such as these could eventually lead to targeted therapies aimed at reducing visceral adiposity. Key Topics Covered: 1. Executive Summary 2. Methodology and Scope 3. Introduction to the Global Anti-obesity Prescription Drugs Market - Obesity Indication Background - Historical and Projected Timeline for Anti-obesity Drugs - Potential Prescribing Behavior Scenario - Regulators' Recommendations for Designing Anti-obesity Drug Clinical Trials - Regional Comparison of Drug Approval Requirements - Global Prevalence of Obesity by Region - Market Overview: Segmentation 4. Competitive Landscape - Anti-obesity Prescription Pharmaceuticals Market: Competitive Landscape - Ongoing Phase 3 Trials for Obesity Drugs - Ongoing Post-marketing Trials for Obesity Drugs - Comparative Efficacy of Obesity Drugs - Pivotal Trial Programs of Recently Approved Anti-obesity Drugs - Pivotal Trial Programs of Late-stage Anti-obesity Drugs - Marketed Products Synopsis - Pipeline Synopsis - Qsymia (phentermine/topiramat ER) - Belviq (lorcaserin HCl) - Contrave (bupropion SR/ naltrexone SR) - Victoza (liraglutide) 5. Conclusions and Recommendations Companies Mentioned - 7TM Pharma - Akrimax Pharmaceuticals - Aliz? Pharma - Alpex Pharma SA - Ami Pharm - Angio Lab - Arena Pharmaceuticals - Arrowhead Research - AstraZeneca - Bridge BioResearch - Boehringer Ingelheim - Compellis Pharmaceuticals - VIVUS - Yungjin Pharm - Zafgen - Zealand Pharma - Zydus Cadila For more information visit http://www.researchandmarkets.com/research/mk..._strategic
Biotech Tweet of the Week: Do Your Due Diligence
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:25PM CDT
Our tweet of the week comes from Mandy Jackson quoting Steve Burrill at a Southern California biotech industry conference, where the venture-capital guru said that his fund looked at 150 companies last year for every one they funded. While...
Active Stocks Technical Review -- Research on Arena Pharma, Yamana Gold, Avon Products, and Banco Bradesco
PR Newswire - Mon May 05, 7:54AM CDT
The markets on Friday, May 02, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,512.89, down 0.28% and the NASDAQ Composite closed at 4,123.90, down 0.09%. The S&P 500 edged 0.13% down, to finish the day at 1,881.14. The losses were broad based as six out of ten sectors finished on a lower note. During the session gains in the Consumer Discretionary, Energy and Materials sectors positively impacted the broader market, while some retraction came in from Information Technology, Health Care and Utilities sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Yamana Gold Inc. (NYSE: AUY), Avon Products Inc. (NYSE: AVP) and Banco Bradesco S.A. (NYSE: BBD). Free technical research on ARNA, AUY, AVP and BBD can be downloaded upon signing up at:
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, May 12
PR Newswire - Mon May 05, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report first quarter 2014 financial results after the NASDAQ Global Select Market closes on Monday, May 12, 2014. That same day, Arena will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Arena Pharma Denied Request Added Market Exclusivity for Weight-Loss Drug
at The Street - Fri May 02, 9:58AM CDT
Citizen Petition filed by Arena's partner Easai is denied by FDA.
Smoking Cessation Therapeutics Pipeline Review 2014 - Detailing 16 Companies & 25 Drug Profiles
M2 - Fri May 02, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6rgwz8/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Smoking Cessation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Johnson & Johnson - Aradigm Corporation - GlaxoSmithKline plc - Pfizer Inc. - Arena Pharmaceuticals, Inc. - Targacept, Inc. - Invion Limited - Marinus Pharmaceuticals, Inc. - Royalty Pharma - Selecta Biosciences, Inc. - Embera NeuroTherapeutics, Inc. - NAL Pharmaceuticals Ltd. - BIOPROJET SCR - Astraea Therapeutics, LLC - Adial Pharmaceuticals, LLC - Istituto Italiano di Tecnologia Drug Profiles - GSK-598809 - lorcaserin hydrochloride - nadolol - ganaxolone - cycloserine - BP-1.4979 - meclizine hydrochloride - zonisamide - ARD-1600 - (oxazepam metyrapone) - ondansetron - SEL-068 - PF-05402536 - PF-06413367 - cycloserine - Small Molecule for Smoking Cessation - nicotine - NIC7-DT - CC-4 - Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Small Molecule for Smoking Cessation - Alpha 4 Beta 2 Neuronal Nicotinic Receptor Agonists for Smoking Cessation - Small Molecules to Inhibit FAAH for CNS Disorders - Nicotine Vaccine - NAL-2762 For more information visit http://www.researchandmarkets.com/research/6r..._cessation
Biotech Earnings Preview
Brian Orelli, The Motley Fool - Motley Fool - Tue Apr 22, 1:00PM CDT
It's Fools' favorite time of the year: earnings season. In the video below, senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss a few biotechs that will release first quarter earnings shortly. Gilead Sciences...
'Mad Money' Lightning Round: Delta Is Flying to $40
at The Street - Wed Apr 16, 5:00AM CDT
Cramer says sell LinkedIn and Arena Pharmaceuticals but buy Constellation Brands.
Jim Cramer's 'Mad Money' Recap: Fear and Loathing on Wall Street
at The Street - Tue Apr 15, 7:08PM CDT
That's what professional money managers are feeling as they try and make sense of the today's market action, Cramer says.
NIRI San Diego to Host Special Luncheon with LinkedIn's Head of Investor Education, Matt Sonefeldt, on May 15
PR Newswire - Tue Apr 15, 1:26PM CDT
The San Diego Chapter of the National Investor Relations Institute (NIRI) will host a special event with LinkedIn's Head of Investor Education, Matt Sonefeldt, on Thursday, May 15, 2014. The luncheon will be held at the corporate headquarters of Arena Pharmaceuticals, Inc. in San Diego, CA.
Arena Pharmaceuticals reports national television advertising campaign for BELVIQ for chronic weight management
M2 - Tue Apr 15, 5:26AM CDT
Biopharmaceutical company Arena Pharmaceuticals (NasdaqGS:ARNA) announced on Monday a national television advertising campaign on Lifetime, Oxygen, AMC and numerous other networks for BELVIQ for chronic weight management.
Arena Pharmaceuticals' Q1 Loss Widens 34% Despite Belviq's Sales Surge
Sean Williams, The Motley Fool - Motley Fool - Mon May 12, 3:50PM CDT
Arena Pharmaceuticals , a biopharmaceutical company primarily focused on weight control management drug Belviq, this afternoon reported strong sales growth of its lead product in the first quarter , but also produced a much wider net loss than in...
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2014 Financial Results
PR Newswire - Mon May 12, 3:03PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2014.
Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ® (lorcaserin HCl) CIV by 50%
PR Newswire - Fri May 09, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai plans to add more than 200 new contract sales representatives to its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600, triple the size from the commercial launch of BELVIQ in June 2013. Eisai expects this expansion of the sales force will become effective on July 1, 2014, and enable them to reach approximately 90,000 physicians in the United States.
Healthcare Companies Report Studies, Financial Results, and Upcoming Conferences - Analyst Notes on Vertex, PerkinElmer, PAREXEL, ACADIA Pharmaceuticals and Arena Pharmaceuticals
PR Newswire - Thu May 08, 11:31AM CDT
Today, Analysts Review released its analysts' notes regarding Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2188-100free.
ARNA June 27th Options Begin Trading
DividendChannel.com - Thu May 08, 10:02AM CDT
Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the June 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new June 27th contracts and identified...
Psoriasis - Pipeline Review, H1 2014: 110 Companies Profiled
M2 - Thu May 08, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vjq8/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 4SC AG - Acceleron Pharma, Inc. - Addex Therapeutics - Advancell - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Alcon, Inc. - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - AngioLab, Inc. - Apexigen, Inc. - ApoPharma Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Aurinia Pharmaceuticals Inc. - Avexxin AS - Basilea Pharmaceutica AG - Bionomics Limited - Brickell Biotech, Inc. - Can-Fite BioPharma Ltd. - Catabasis Pharmaceuticals, Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Cellceutix Corporation - Celltrion, Inc. For more information visit http://www.researchandmarkets.com/research/p6vjq8/psoriasis
Acute Coronary Syndrome - Pipeline Review, H1 2014: 21 Companies and 29 Drugs Profiled
M2 - Wed May 07, 12:15PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2f56rx/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Bayer AG - CSL Limited - GlaxoSmithKline plc - LG Life Sciences, Ltd. - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - Ligand Pharmaceuticals, Inc. - MedImmune, LLC - Medicure Inc. - Pfizer Inc. - Regado Biosciences, Inc. - Stealth Peptides Inc. - The Medicines Company - Viron Therapeutics, Inc. - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles: - cangrelor - rivaroxaban - BAY-818781 - REG-1 - clopidogrel bisulfate - VT-111a - CSL-112 - gevokizumab - losmapimod - MTP-131 - ZK-001 - PR-15 - temanogrel hydrochloride - MDCO-216 - losmapimod - LC-231306 - ACP-501 - PF-06282999 - Artpep-2 - DMI-4983 - LA-8045 - COR-3 - COR-2 - AEM-28 - Type 5 Adenylyl Cyclase Inhibitors - tirofiban hydrochloride transdermal - Liver X Receptor Modulator For Acute Coronary Syndrome - Anti Platelet Program - SD-970 For more information visit http://www.researchandmarkets.com/research/2f...e_coronary
A View on Ariad Pharma's Bloated Valuation
at The Street - Wed May 07, 11:49AM CDT
Even at $86 million in 2014 Iclusig sales, Ariad trades at a lofty and unjustified 13 times enterprise value. For comparison's sake, Medivation's EV/sales multiple is 9 -- and that's only counting U.S. sales of its growing prostate cancer drug...
VIVUS Blows Out Estimates, But For All the Wrong Reasons
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 9:03AM CDT
After the closing bell on Monday, VIVUS shares entered unchartered territory following the release of its first-quarter earnings report -- and by unchartered I mean actually up . VIVUS hasn't had the best of luck come earnings time. In fact,...
Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market 2014
M2 - Tue May 06, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mk3bhv/a_strategic) has announced the addition of the "A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market" report to their offering. Prescription drug therapy for the treatment of obesity is experiencing a revival of interest with new government incentives and the recent approval of 2 new drugs, with 2 more pending imminent approval. This research service focuses on the competitive landscape of prescription drugs for the treatment of obesity. A global product and pipeline assessment is provided for marketed and investigational products. Segmentation by drug class is provided along with additional supporting information, such as clinical-trial timelines and results, historical and projected launch timelines, regulatory guidelines for clinical trial design and approval, and global epidemiology by region. Executive Summary: - The FDA recently approved 2 new prescription obesity treatments: Arena Pharmaceuticals' Belviq (partnered with Eisai) launched in June 2013, and Vivus' Qsymia, which became available September 2012. These FDA approvalsthe first for obesity in more than a decadeadd new therapeutic options to a market previously comprising a single approved drug: Roche's Xenical. - A third new drug, Orexigen's Contrave, is pending FDA approval upon successful demonstration of cardiac safety in an ongoing trial for cardiovascular outcomes and resubmission of the new drug application (NDA) in December 2013. A decision is expected from the FDA June 10, 2014, and in the second half of 2014 from the EMA. o All three of these new drugs were initially rejected by the FDA, which sought additional confirmation of an acceptable safety profile. - Approval of the obesity indication for Novo Nordisk's Victoza (liraglutide) could come as soon as mid-2014, closely coinciding with the potential approval of Contrave. - Market uptake of Qsymia and Belviq has been below expectations, largely due to insurance reimbursement hurdles and possibly because of physician and patient concerns about safety. Contrave, if approved, may have better uptake in light of its designation as an uncontrolled substance and stronger marketing capabilities of partner Takeda, particularly to the primary care and diabetes communities. - Global medical and regulatory communities recognize the urgent need for the pharmacotherapeutic treatment of obesity when lifestyle interventions fail to adequately address excess body fat. - While numerous sympathomimetic amine anorectics such as phentermine, benzphetamine, and diethylpropion are available by prescription, association with serious side effects limits their use, and prescribing is mainly limited to bariatric surgeons. - The global market potential for safe and effective obesity therapies is significant; howeverthe discovery and development of efficacious weight-loss drugs that are safe enough for - chronic use has proved challenging for even the most capable pharmaceutical and biotech companies. - Ongoing research efforts are beginning to shed new light on the pathology of obesity, as recent discoveries of differential gene expression and genetic variants found in the different fat depots advance our understanding of why abdominal fat is more strongly associated with morbidity and mortality compared with subcutaneous adipose tissue. Discoveries such as these could eventually lead to targeted therapies aimed at reducing visceral adiposity. Key Topics Covered: 1. Executive Summary 2. Methodology and Scope 3. Introduction to the Global Anti-obesity Prescription Drugs Market - Obesity Indication Background - Historical and Projected Timeline for Anti-obesity Drugs - Potential Prescribing Behavior Scenario - Regulators' Recommendations for Designing Anti-obesity Drug Clinical Trials - Regional Comparison of Drug Approval Requirements - Global Prevalence of Obesity by Region - Market Overview: Segmentation 4. Competitive Landscape - Anti-obesity Prescription Pharmaceuticals Market: Competitive Landscape - Ongoing Phase 3 Trials for Obesity Drugs - Ongoing Post-marketing Trials for Obesity Drugs - Comparative Efficacy of Obesity Drugs - Pivotal Trial Programs of Recently Approved Anti-obesity Drugs - Pivotal Trial Programs of Late-stage Anti-obesity Drugs - Marketed Products Synopsis - Pipeline Synopsis - Qsymia (phentermine/topiramat ER) - Belviq (lorcaserin HCl) - Contrave (bupropion SR/ naltrexone SR) - Victoza (liraglutide) 5. Conclusions and Recommendations Companies Mentioned - 7TM Pharma - Akrimax Pharmaceuticals - Aliz? Pharma - Alpex Pharma SA - Ami Pharm - Angio Lab - Arena Pharmaceuticals - Arrowhead Research - AstraZeneca - Bridge BioResearch - Boehringer Ingelheim - Compellis Pharmaceuticals - VIVUS - Yungjin Pharm - Zafgen - Zealand Pharma - Zydus Cadila For more information visit http://www.researchandmarkets.com/research/mk..._strategic
Biotech Tweet of the Week: Do Your Due Diligence
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:25PM CDT
Our tweet of the week comes from Mandy Jackson quoting Steve Burrill at a Southern California biotech industry conference, where the venture-capital guru said that his fund looked at 150 companies last year for every one they funded. While...
Active Stocks Technical Review -- Research on Arena Pharma, Yamana Gold, Avon Products, and Banco Bradesco
PR Newswire - Mon May 05, 7:54AM CDT
The markets on Friday, May 02, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,512.89, down 0.28% and the NASDAQ Composite closed at 4,123.90, down 0.09%. The S&P 500 edged 0.13% down, to finish the day at 1,881.14. The losses were broad based as six out of ten sectors finished on a lower note. During the session gains in the Consumer Discretionary, Energy and Materials sectors positively impacted the broader market, while some retraction came in from Information Technology, Health Care and Utilities sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Yamana Gold Inc. (NYSE: AUY), Avon Products Inc. (NYSE: AVP) and Banco Bradesco S.A. (NYSE: BBD). Free technical research on ARNA, AUY, AVP and BBD can be downloaded upon signing up at:
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, May 12
PR Newswire - Mon May 05, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report first quarter 2014 financial results after the NASDAQ Global Select Market closes on Monday, May 12, 2014. That same day, Arena will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Arena Pharma Denied Request Added Market Exclusivity for Weight-Loss Drug
at The Street - Fri May 02, 9:58AM CDT
Citizen Petition filed by Arena's partner Easai is denied by FDA.
Smoking Cessation Therapeutics Pipeline Review 2014 - Detailing 16 Companies & 25 Drug Profiles
M2 - Fri May 02, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6rgwz8/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Smoking Cessation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Johnson & Johnson - Aradigm Corporation - GlaxoSmithKline plc - Pfizer Inc. - Arena Pharmaceuticals, Inc. - Targacept, Inc. - Invion Limited - Marinus Pharmaceuticals, Inc. - Royalty Pharma - Selecta Biosciences, Inc. - Embera NeuroTherapeutics, Inc. - NAL Pharmaceuticals Ltd. - BIOPROJET SCR - Astraea Therapeutics, LLC - Adial Pharmaceuticals, LLC - Istituto Italiano di Tecnologia Drug Profiles - GSK-598809 - lorcaserin hydrochloride - nadolol - ganaxolone - cycloserine - BP-1.4979 - meclizine hydrochloride - zonisamide - ARD-1600 - (oxazepam metyrapone) - ondansetron - SEL-068 - PF-05402536 - PF-06413367 - cycloserine - Small Molecule for Smoking Cessation - nicotine - NIC7-DT - CC-4 - Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Small Molecule for Smoking Cessation - Alpha 4 Beta 2 Neuronal Nicotinic Receptor Agonists for Smoking Cessation - Small Molecules to Inhibit FAAH for CNS Disorders - Nicotine Vaccine - NAL-2762 For more information visit http://www.researchandmarkets.com/research/6r..._cessation
Biotech Earnings Preview
Brian Orelli, The Motley Fool - Motley Fool - Tue Apr 22, 1:00PM CDT
It's Fools' favorite time of the year: earnings season. In the video below, senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss a few biotechs that will release first quarter earnings shortly. Gilead Sciences...
'Mad Money' Lightning Round: Delta Is Flying to $40
at The Street - Wed Apr 16, 5:00AM CDT
Cramer says sell LinkedIn and Arena Pharmaceuticals but buy Constellation Brands.
Jim Cramer's 'Mad Money' Recap: Fear and Loathing on Wall Street
at The Street - Tue Apr 15, 7:08PM CDT
That's what professional money managers are feeling as they try and make sense of the today's market action, Cramer says.
NIRI San Diego to Host Special Luncheon with LinkedIn's Head of Investor Education, Matt Sonefeldt, on May 15
PR Newswire - Tue Apr 15, 1:26PM CDT
The San Diego Chapter of the National Investor Relations Institute (NIRI) will host a special event with LinkedIn's Head of Investor Education, Matt Sonefeldt, on Thursday, May 15, 2014. The luncheon will be held at the corporate headquarters of Arena Pharmaceuticals, Inc. in San Diego, CA.
Arena Pharmaceuticals reports national television advertising campaign for BELVIQ for chronic weight management
M2 - Tue Apr 15, 5:26AM CDT
Biopharmaceutical company Arena Pharmaceuticals (NasdaqGS:ARNA) announced on Monday a national television advertising campaign on Lifetime, Oxygen, AMC and numerous other networks for BELVIQ for chronic weight management.
